Aditxt (NASDAQ:ADTX – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Aditxt and Organon & Co., as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 17.12%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Aditxt.
Insider & Institutional Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Aditxt and Organon & Co.”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
| Organon & Co. | $6.22 billion | 0.58 | $187.00 million | $0.77 | 17.86 |
Organon & Co. has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aditxt has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Profitability
This table compares Aditxt and Organon & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Organon & Co. | 3.41% | 88.97% | 6.03% |
Summary
Organon & Co. beats Aditxt on 13 of the 13 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
